Keros Therapeutics, Inc
Price
FilingsNewest: 8-K, Regulation FD disclosureSep 29 →Insiders1 insider bought $54,890 in 4 open-market buys. 20 insiders sold $181.1M, 4 of 15 sales on a 10b5-1 plan.→HoldersNantahala 14.2%BlackRock 14.1%AQR 4.9%→Financing →PeersClosest companies: DYN, CGEM, ALEC→
From the filings
Figures
- Revenue
- $15.0Mlast 12 months
- Net income
- −$83.2Mlast 12 months
- Operating cash flow
- −$57.2Mlast 12 months
- Cash and equivalents
- $257.6Mat the last balance sheet
- Shares outstanding
- 19.8M shareson issue